Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber International, spotlights key lung cancer updates from ESMO25:
“Tarlatamab incorporated upfront with chemo-immunotherapy breaks all the known stats in first-line SCLC.
No new data safety concerns. Awaiting data from randomized ph3 trial, but likely to be the next SoC.”
“MDT-BRIDGE broaden the population finally considered for surgery in borderline resectable NSCLC with just 2 cycles of neoadjuvant chemo-Durva. 27% pCR with acceptable surgical outcomes.
Martin Reck showed the importance of longitudinal MTD decisions.”
“Anti-TIGIT fails again (I can’t remember how many times I have posted negative results of these agents)
Tiragolumab + atezolizumab did not improve PFS versus durvalumab in unresectable stage III NSCLC after chemoradiation in SKYSCRAPER-03 trial.”
You can also read: ESMO 2025 Day 1 Highlights Not to Miss
